You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股異動丨海正藥業再度漲停 獨有法匹拉韋生產批號 二股東卻減持
格隆匯 03-19 13:57
格隆匯3月19日丨海正藥業(600267.SH)再度漲停,報15.68元,總市值151.4億元。在3月17日,國務院聯防聯控機制舉行的新聞發佈會上,科技部生物中心主任張新民介紹,法匹拉韋已完成臨牀研究,顯示出良好臨牀療效,且未出現明顯不良反應。張新民表示,法匹拉韋已實現量產,臨牀供應有保障。經過科研攻關組專家充分論證,已正式向醫療救治組推薦,建議儘快納入診療方案。據國家藥監局披露,目前,法匹拉韋產品僅有海正藥業擁有生產批號,批准日期顯示為2020年2月15日,系目前國內獲批的唯一一家企業。就在3月17日晚間,海正藥業公佈,截止本公告披露日,公司持股5%以上股東國貿集團持有公司無限售條件流通股8652.49萬股,佔公司總股本的8.96%;國貿集團的一致行動人英特藥業持有公司無限售條件流通股205.771萬股,佔公司總股本的0.21%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account